** Shares of Cambium Bio CMB.AX up as much as 30.2% to A$0.28, hitting highest level since April 24
** Regenerative medicine maker says it cleared US FDA's regulatory requirements to initiate patient dosing in its Phase 3 clinical trials of Elate Ocular which can be used to treat dry eye disease
** About 93,600 shares change hands, 18x the 30-day average
** Stock down 30% YTD, at current levels
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。